A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction

Journal of the American College of Cardiology

Volumn 30, Issue 5, 1997, Pages 1206-1211

  Anderson, Jeffrey L ^a   King, Gretchen J ^a   Thomson, Matthew J ^a   Todd, Michael ^a   Bair, Tami L ^a   Muhlestein, Joseph B ^a   Carlquist, John F ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; HEART INFARCTION; HOMOGENATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; CONSTRICTION, PATHOLOGIC; CORONARY DISEASE; FEMALE; GENES; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; MYOCARDIAL INFARCTION; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 0030859681     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00310-0     Document Type: Article

References (32)

1. Kang SS, Wong PW, Susmano A, Sora J, Narusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase an inherited risk factor for coronary artery disease . Am J Hum Genet. 48:1991;536-545.
2. Kang SS, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 88:1993;1463-1469.
3. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5′,10′-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 56:1995;142-150.
4. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease a common mutation in methylenetetrahydrofolate reductase . Nat Genet. 10:1995;111-113.
5. van der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 346:1995;1070-1071.
6. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
7. McCully KS. Vascular pathology of homocysteinemia implications for the pathogenesis of arteriosclerosis . Am J Pathol. 56:1969;111-128.
8. Rosenblatt DS. Inherited disorders of folate transport and metabolism. Scriver CR, Beaudet AL, Sly WS, Valle D. 7th ed. The Metabolic and Molecular Bases of Inherited Disease. Vol I:1995;3111-3128 McGraw-Hill, New York.
9. Genest JJ Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocysteinemia levels in men with premature coronary artery disease. J Am Coll Cardiol. 16:1990;1114-1119.
10. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate common and independent reversible risk factors for coronary artery disease . Circulation. 92:1995;2825-2830.
11. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine risk of myocardial infarction in US physicians. JAMA. 268:1992;877-881.
12. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 24:1995;704-709.
13. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke prevalence, cause, and relationships to type of stroke and stroke risk factors . Eur J Clin Invest. 22:1992;214-221.
14. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willet WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 25:1994;1924-1930.
15. Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease effects of pyridoxine and folic acid treatment . Atherosclerosis. 81:1990;51-60.
16. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 332:1995;286-291.
17. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults the Atherosclerosis Risk in Communities Study . Circulation. 87:1993;1107-1113.
18. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 334:1996;759-762.
19. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease probable benefits of increasing folic acid intakes . JAMA. 274:1995;1049-1057.
20. Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 36:1987;458-462.
21. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest. 81:1988;466-474.
22. 12, and folate . Am J Epidemiol. 143:1996;845-859.
23. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 270:1993;2693-2698.
24. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease . Am J Hum Genet. 58:1996;35-41.
25. Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. QJM. 88:1995;763-766.
26. McClellan T, Jorde LB, Skolnick MH. Genetic distances between the Utah Mormons and related populations. Am J Hum Genet. 36:1984;836-857.
27. Myocardial infarction and mortality in the Coronary Artery Surgery Study (CASS) randomized trial. N Engl J Med. 310:1984;750-754.
28. Marshall HW, Morrison LC, Wu LL, et al. Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Circulation. 89:1994;567-577.
29. Carlquist JF, Ward RH, Meyer KJ, Husebye D, Feolo M, Anderson JL. Immune response factors in rheumatic heart disease meta-analysis of HLA-DR associations and evaluation of additional class II alleles . J Am Coll Cardiol. 26:1995;452-457.
30. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. Circulation. 94:1996;1812-1814.
31. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
32. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21-23.